203 related articles for article (PubMed ID: 28938670)
1. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies.
Wang Y; Xiong J; Niu M; Chen X; Gao L; Wu Q; Zheng K; Xu K
Oncotarget; 2017 Aug; 8(35):59666-59676. PubMed ID: 28938670
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
Huang YW; Lee CL; Yang SS; Fu SC; Chen YY; Wang TC; Hu JT; Chen DS
Am J Gastroenterol; 2016 Jul; 111(7):976-85. PubMed ID: 27166128
[TBL] [Abstract][Full Text] [Related]
4. Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies.
Islam MM; Poly TN; Walther BA; Yang HC; Jack Li YC
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183029
[No Abstract] [Full Text] [Related]
5. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
[TBL] [Abstract][Full Text] [Related]
6. Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis.
Li Z; Li Y; Li X; Zhang L; Zhao N; Du H; Zhou B; Ye Y
Turk J Gastroenterol; 2022 Feb; 33(2):136-144. PubMed ID: 35115293
[TBL] [Abstract][Full Text] [Related]
7. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
Yang YH; Chen WC; Tsan YT; Chen MJ; Shih WT; Tsai YH; Chen PC
J Hepatol; 2015 Nov; 63(5):1111-7. PubMed ID: 26196278
[TBL] [Abstract][Full Text] [Related]
8. Statin use and the risk of
Tariq R; Mukhija D; Gupta A; Singh S; Pardi DS; Khanna S
Infect Drug Resist; 2018; 11():405-416. PubMed ID: 29559802
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
10. Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis.
Li Z; Li Y; Li X; Zhang L; Zhao N; Du H; Zhou B; Ye Y
Medicine (Baltimore); 2018 Aug; 97(34):e11950. PubMed ID: 30142817
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Alfaiate D; Clément S; Gomes D; Goossens N; Negro F
J Hepatol; 2020 Sep; 73(3):533-539. PubMed ID: 32151618
[TBL] [Abstract][Full Text] [Related]
12. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
Zheng YX; Zhou PC; Zhou RR; Fan XG
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
[TBL] [Abstract][Full Text] [Related]
13. [Meta-analysis of the effects of statins on the risk of chronic liver disease and hepatocellular carcinoma].
Wei J; Lvy JH; Sun XJ; Wu XR
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):696-701. PubMed ID: 34371542
[No Abstract] [Full Text] [Related]
14. Meta-analysis of studies using statins as a reducer for primary liver cancer risk.
Zhong GC; Liu Y; Ye YY; Hao FB; Wang K; Gong JP
Sci Rep; 2016 May; 6():26256. PubMed ID: 27198922
[TBL] [Abstract][Full Text] [Related]
15. Statin use and virus-related cirrhosis: A systemic review and meta-analysis.
Ma X; Sun D; Li C; Ying J; Yan Y
Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):533-542. PubMed ID: 28866088
[TBL] [Abstract][Full Text] [Related]
16. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
Kamal S; Khan MA; Seth A; Cholankeril G; Gupta D; Singh U; Kamal F; Howden CW; Stave C; Nair S; Satapathy SK; Ahmed A
Am J Gastroenterol; 2017 Oct; 112(10):1495-1505. PubMed ID: 28585556
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis.
Xiong J; Zhang H; Wang Y; Wang A; Bian J; Huang H; Zheng Y; Sang X; Xu Y; Lu X; Zhao H
Oncotarget; 2017 Dec; 8(63):107295-107302. PubMed ID: 29291029
[TBL] [Abstract][Full Text] [Related]
18. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
